Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vicky Makker

Showing results (121-130 of 140) with videos related to

Pageof 14
Sort By:
Investigational New Drugs|March 11, 2017
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxelLillian M Smyth, Kelsey R Monson, Komal Jhaveri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2015
Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian CancerRachel N Grisham, Brooke E Sylvester, Helen Won, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2026
A Phase II Trial of Olaparib Plus Pembrolizumab in Patients with Recurrent Copy-Number High/p53-Abnormal Endometrial CancerMaria M Rubinstein, Jennifer Y Ge, Qin Zhou, et al.
The New England Journal of Medicine|January 19, 2022
Lenvatinib plus Pembrolizumab for Advanced Endometrial CancerVicky Makker, Nicoletta Colombo, Antonio Casado Herráez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2024
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III TrialChristian Marth, Richard G Moore, Mariusz Bidziński, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 6, 2026
First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trialChristian Marth, Richard G Moore, Mariusz Bidziński, et al.
Gynecologic Oncology|May 7, 2023
Germline drivers of gynecologic carcinosarcomasTiffany Y Sia, Sushmita B Gordhandas, Ozge Birsoy, et al.
Journal for Immunotherapy of Cancer|June 13, 2025
Phase II study of rucaparib and nivolumab in patients with leiomyosarcomaSujana Movva, Kenneth Seier, Martina Bradic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2023
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial CancerIgnace Vergote, Jose Alejandro Pérez-Fidalgo, Erika Paige Hamilton, et al.
Cancer|October 27, 2023
Pathogenic germline variants in patients with endometrial cancer of diverse ancestryYing L Liu, Sushmita Gordhandas, Kanika Arora, et al.
Pageof 14

Showing results (121-130 of 140) with videos related to

Sort By:
Pageof 14
Investigational New Drugs|March 11, 2017
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxelLillian M Smyth, Kelsey R Monson, Komal Jhaveri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2015
Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian CancerRachel N Grisham, Brooke E Sylvester, Helen Won, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2026
A Phase II Trial of Olaparib Plus Pembrolizumab in Patients with Recurrent Copy-Number High/p53-Abnormal Endometrial CancerMaria M Rubinstein, Jennifer Y Ge, Qin Zhou, et al.
The New England Journal of Medicine|January 19, 2022
Lenvatinib plus Pembrolizumab for Advanced Endometrial CancerVicky Makker, Nicoletta Colombo, Antonio Casado Herráez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2024
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III TrialChristian Marth, Richard G Moore, Mariusz Bidziński, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 6, 2026
First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trialChristian Marth, Richard G Moore, Mariusz Bidziński, et al.
Gynecologic Oncology|May 7, 2023
Germline drivers of gynecologic carcinosarcomasTiffany Y Sia, Sushmita B Gordhandas, Ozge Birsoy, et al.
Journal for Immunotherapy of Cancer|June 13, 2025
Phase II study of rucaparib and nivolumab in patients with leiomyosarcomaSujana Movva, Kenneth Seier, Martina Bradic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2023
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial CancerIgnace Vergote, Jose Alejandro Pérez-Fidalgo, Erika Paige Hamilton, et al.
Cancer|October 27, 2023
Pathogenic germline variants in patients with endometrial cancer of diverse ancestryYing L Liu, Sushmita Gordhandas, Kanika Arora, et al.
Pageof 14